Core Viewpoint - H&H International Holdings (01112) reported strong Q3 performance with a 28.1% year-on-year revenue increase to HKD 3.79 billion, driven by exceptional growth in the BNC segment, particularly in infant formula [1][2] Performance Summary - For the first nine months of 2025, revenue reached HKD 10.81 billion, reflecting a 12% year-on-year increase, with Q3 revenue at HKD 3.79 billion, up 28.1% year-on-year, exceeding market expectations primarily due to infant formula growth [1][3] Segment Performance - **BNC (Infant Formula)**: Q3 revenue surged 90.6% to HKD 1.47 billion, with infant formula sales up 104% to HKD 1.23 billion. The market share in China's ultra-premium infant formula segment increased to 17.3% due to ongoing investments in maternal and e-commerce channels [2] - **ANC (Adult Nutrition)**: Q3 revenue grew 5.6% (6.3% on a comparable basis) to HKD 1.8 billion, with a 15.7% year-on-year increase in the China region, now accounting for 70.6% of total revenue. Cross-border e-commerce and Douyin channels showed significant growth [2] - **PNC (Pet Nutrition)**: Q3 revenue increased 7.3% to HKD 510 million, with steady performance in both China and North America [2] Future Outlook - The company is expected to achieve high single to low double-digit revenue growth in 2025, with all three segments maintaining positive growth trends. Profit margins are anticipated to remain healthy, supported by ongoing financial cost optimization [3] Earnings Forecast and Valuation - The earnings forecast for 2025 and 2026 has been raised by 5.1% and 4.3% to HKD 670 million and HKD 790 million, respectively. The current trading multiples are 12x and 10x for 2025 and 2026 P/E, with a target price of HKD 17.7, indicating a 29% upside potential [4]

Investment Rating - The report maintains a "Buy" rating for H&H International Holdings (1112.HK) [1][4] Core Views - The company's performance in the first half of 2025 met previous forecasts, with revenue of HKD 7.02 billion, a year-on-year increase of 4.9% [4] - The report highlights the continuous market share growth of the company's infant formula brand, with a significant increase in the ultra-premium segment in mainland China [4] - The report projects total revenue for 2025-2027 to be HKD 14.37 billion, HKD 15.49 billion, and HKD 16.44 billion respectively, with net profit estimates of HKD 676 million, HKD 845.5 million, and HKD 952.9 million [1][4] Revenue and Profit Analysis - In the first half of 2025, the revenue from the ANC (Adult Nutrition and Care) business was HKD 3.44 billion, up 5.0% year-on-year, with mainland China contributing HKD 4.94 billion, a growth of 8.7% [4] - The BNC (Baby Nutrition and Care) segment achieved revenue of HKD 2.50 billion, a 2.9% increase, with a notable 10.0% growth in mainland China [4] - The PNC (Pet Nutrition and Care) business reported revenue of HKD 1.08 billion, reflecting a 9.6% increase, driven by a successful high-end strategy [4] Financial Forecasts - The report forecasts total revenue for 2024A at HKD 13.05 billion, with a projected growth rate of -6.3% [5] - The estimated diluted earnings per share for 2025E is HKD 1.05, with a P/E ratio of 13.27 based on the current price [5] - The report maintains the target price at HKD 16.9, indicating potential upside from the current market price [4][5]